title: Memantine (Ebixa) in the later stages of dementia.
abstract: Memantine is the first agent licensed for the treatment of moderate to severe Alzheimer's disease. It is an N-methyl D-aspartate (NMDA) receptor antagonist which reduces glutamatergic excitotoxicity. Benefits are seen in cognitive, functional and global measures in both outpatients and nursing home residents. Prospective health economic benefits have been reported.
authors.affiliation: Department of Old Age Psychiatry, Royal Dundee Liff Hospital, Dundee DD2 5NF.
authors.forename: David J
authors.initials: DJ
authors.lastname: Findlay
authors.forename: Peter J
authors.initials: PJ
authors.lastname: Connelly
mesh_terms: D000978:Antiparkinson Agents / Q000627:therapeutic use*; D002908:Chronic Disease; D002986:Clinical Trials as Topic; D003704:Dementia / Q000188:drug therapy*; D015140:Dementia, Vascular / Q000188:drug therapy; D006801:Humans; D008559:Memantine / Q000627:therapeutic use*
chemical_list: D000978:Antiparkinson Agents; D008559:Memantine